2019
Jiřík, Radovan; Taxt, Torfinn; Macíček, Ondřej; Bartoš, Michal; Kratochvíla, Jiří; Souček, Karel; Dražanová, Eva; Krátká, Lucie; Hampl, Aleš; Starčuk, Zenon Jr
Blind deconvolution estimation of an arterial input function for small animal DCE-MRI. Journal Article
In: Magnetic resonance imaging, vol. 62, pp. 46–56, 2019, ISSN: 1873-5894 0730-725X, (Place: Netherlands).
Abstract | Links | BibTeX | Tags: *Magnetic Resonance Imaging, Algorithms, Animals, Arterial input function, Arteries/*diagnostic imaging, Blind deconvolution, Computer Simulation, Computer-Assisted/*methods, Contrast Media/*pharmacokinetics, DCE-MRI, Humans, Image Processing, Inbred BALB C, Mice, Necrosis/pathology, Perfusion, Pharmacokinetics, Regression Analysis, Reproducibility of Results, Signal-To-Noise Ratio
@article{jirik_blind_2019,
title = {Blind deconvolution estimation of an arterial input function for small animal DCE-MRI.},
author = {Radovan Jiřík and Torfinn Taxt and Ondřej Macíček and Michal Bartoš and Jiří Kratochvíla and Karel Souček and Eva Dražanová and Lucie Krátká and Aleš Hampl and Zenon Jr Starčuk},
doi = {10.1016/j.mri.2019.05.024},
issn = {1873-5894 0730-725X},
year = {2019},
date = {2019-10-01},
journal = {Magnetic resonance imaging},
volume = {62},
pages = {46–56},
abstract = {PURPOSE: One of the main obstacles for reliable quantitative dynamic contrast-enhanced (DCE) MRI is the need for accurate knowledge of the arterial input function (AIF). This is a special challenge for preclinical small animal applications where it is very difficult to measure the AIF without partial volume and flow artifacts. Furthermore, using advanced pharmacokinetic models (allowing estimation of blood flow and permeability-surface area product in addition to the classical perfusion parameters) poses stricter requirements on the accuracy and precision of AIF estimation. This paper addresses small animal DCE-MRI with advanced pharmacokinetic models and presents a method for estimation of the AIF based on blind deconvolution. METHODS: A parametric AIF model designed for small animal physiology and use of advanced pharmacokinetic models is proposed. The parameters of the AIF are estimated using multichannel blind deconvolution. RESULTS: Evaluation on simulated data show that for realistic signal to noise ratios blind deconvolution AIF estimation leads to comparable results as the use of the true AIF. Evaluation on real data based on DCE-MRI with two contrast agents of different molecular weights showed a consistence with the known effects of the molecular weight. CONCLUSION: Multi-channel blind deconvolution using the proposed AIF model specific for small animal DCE-MRI provides reliable perfusion parameter estimates under realistic signal to noise conditions.},
note = {Place: Netherlands},
keywords = {*Magnetic Resonance Imaging, Algorithms, Animals, Arterial input function, Arteries/*diagnostic imaging, Blind deconvolution, Computer Simulation, Computer-Assisted/*methods, Contrast Media/*pharmacokinetics, DCE-MRI, Humans, Image Processing, Inbred BALB C, Mice, Necrosis/pathology, Perfusion, Pharmacokinetics, Regression Analysis, Reproducibility of Results, Signal-To-Noise Ratio},
pubstate = {published},
tppubtype = {article}
}
PURPOSE: One of the main obstacles for reliable quantitative dynamic contrast-enhanced (DCE) MRI is the need for accurate knowledge of the arterial input function (AIF). This is a special challenge for preclinical small animal applications where it is very difficult to measure the AIF without partial volume and flow artifacts. Furthermore, using advanced pharmacokinetic models (allowing estimation of blood flow and permeability-surface area product in addition to the classical perfusion parameters) poses stricter requirements on the accuracy and precision of AIF estimation. This paper addresses small animal DCE-MRI with advanced pharmacokinetic models and presents a method for estimation of the AIF based on blind deconvolution. METHODS: A parametric AIF model designed for small animal physiology and use of advanced pharmacokinetic models is proposed. The parameters of the AIF are estimated using multichannel blind deconvolution. RESULTS: Evaluation on simulated data show that for realistic signal to noise ratios blind deconvolution AIF estimation leads to comparable results as the use of the true AIF. Evaluation on real data based on DCE-MRI with two contrast agents of different molecular weights showed a consistence with the known effects of the molecular weight. CONCLUSION: Multi-channel blind deconvolution using the proposed AIF model specific for small animal DCE-MRI provides reliable perfusion parameter estimates under realistic signal to noise conditions.
Šimek, Matěj; Hermannová, Martina; Šmejkalová, Daniela; Foglová, Tereza; Souček, Karel; Binó, Lucia; Velebný, Vladimír
LC-MS/MS study of in vivo fate of hyaluronan polymeric micelles carrying doxorubicin. Journal Article
In: Carbohydrate polymers, vol. 209, pp. 181–189, 2019, ISSN: 1879-1344 0144-8617, (Place: England).
Abstract | Links | BibTeX | Tags: *Micelles, Animals, Biodistribution, Chromatography, Doxorubicin, Doxorubicin/*chemistry/pharmacokinetics, Drug Carriers/*chemistry, Drug Liberation, Female, Hyaluronan, Hyaluronic Acid/*chemistry, Liquid, Mice, Molecular Weight, Pharmacokinetics, Polymeric micelles, Tandem Mass Spectrometry, Tissue Distribution
@article{simek_lc-msms_2019,
title = {LC-MS/MS study of in vivo fate of hyaluronan polymeric micelles carrying doxorubicin.},
author = {Matěj Šimek and Martina Hermannová and Daniela Šmejkalová and Tereza Foglová and Karel Souček and Lucia Binó and Vladimír Velebný},
doi = {10.1016/j.carbpol.2018.12.104},
issn = {1879-1344 0144-8617},
year = {2019},
date = {2019-04-01},
journal = {Carbohydrate polymers},
volume = {209},
pages = {181–189},
abstract = {A better understanding of in vivo behavior of nanocarriers is necessary for further improvement in their development. Here we present a novel approach, where both the matrix and the drug can be analyzed by LCMS/MS after one sample handling. The developed method was applied for the comparison of pharmacokinetic profile of free and encapsulated doxorubicin (DOX) in oleyl hyaluronan (HA-C18:1) polymeric micelles. The results indicated that nanocarriers were rapidly dissociated upon in vivo administration. Despite this fact, the administration of encapsulated DOX led to its longer circulation time and enhanced tumor targeting. This effect was not observed injecting blank HA-C18:1 micelles followed by unencapsulated DOX. Biodistribution studies and molecular weight estimation of the carrier matrix indicated relatively high stability of HA-C18:1 ester bond in bloodstream and complete elimination of the derivative within 72 h. The proposed methodology provides a novel strategy to elucidate the pharmacokinetic behavior of polysaccharide-based drug delivery systems.},
note = {Place: England},
keywords = {*Micelles, Animals, Biodistribution, Chromatography, Doxorubicin, Doxorubicin/*chemistry/pharmacokinetics, Drug Carriers/*chemistry, Drug Liberation, Female, Hyaluronan, Hyaluronic Acid/*chemistry, Liquid, Mice, Molecular Weight, Pharmacokinetics, Polymeric micelles, Tandem Mass Spectrometry, Tissue Distribution},
pubstate = {published},
tppubtype = {article}
}
A better understanding of in vivo behavior of nanocarriers is necessary for further improvement in their development. Here we present a novel approach, where both the matrix and the drug can be analyzed by LCMS/MS after one sample handling. The developed method was applied for the comparison of pharmacokinetic profile of free and encapsulated doxorubicin (DOX) in oleyl hyaluronan (HA-C18:1) polymeric micelles. The results indicated that nanocarriers were rapidly dissociated upon in vivo administration. Despite this fact, the administration of encapsulated DOX led to its longer circulation time and enhanced tumor targeting. This effect was not observed injecting blank HA-C18:1 micelles followed by unencapsulated DOX. Biodistribution studies and molecular weight estimation of the carrier matrix indicated relatively high stability of HA-C18:1 ester bond in bloodstream and complete elimination of the derivative within 72 h. The proposed methodology provides a novel strategy to elucidate the pharmacokinetic behavior of polysaccharide-based drug delivery systems.